Filing Flows › Haemonetics (HAE) › Q1 FY26
Haemonetics (HAE) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 7, 2025
Haemonetics (HAE) reported revenue of $321M for the first quarter fiscal 2026 (Q1 FY26), -4% from a year earlier and -3% from the quarter before. Operating margin was 16.8%, net earnings $34.0M (10.6% of revenue).
Haemonetics, Q1 FY26: revenue $321M (-4% year over year), operating margin 16.8%, net earnings $34.0M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $321M | -3% | -4% |
| Gross profit | $192M | -0.4% | +10% |
| Operating profit | $53.9M | -24% | +36% |
| Net earnings | $34.0M | -41% | -11% |
| Operating cash flow | $17.4M | -85% | — |
| Free cash flow | $2.5M | — | — |
What changed
Revenue was $321.4M in Q1 FY26, down 4% year over year and down 3% from the previous quarter. Hospital was the largest line at 43% of revenue. Blood Center lost $14.4M year over year (down 22%), 97% of the total change.
Gross margin was 59.8%, up 7.8 points from a year earlier. Operating profit was $53.9M, a 16.8% margin (up 4.9 points year over year). Operating expenses grew 2% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+13%). Net earnings were $34.0M, down 11% year over year. The effective tax rate was 24.7%.
Operating cash flow was $17.4M, 51% of net earnings. Non-cash charges added back $28.8M of depreciation and amortization and $9.3M of share-based compensation. Working capital and other items used $54.7M. After itions to Haemonetics equipment, net ($11.2M) and capital expenditures ($3.8M), free cash flow as the company reports it was $2.5M.
Questions
What was Haemonetics' revenue in the first quarter fiscal 2026?
Haemonetics (HAE) reported revenue of $321M for the first quarter fiscal 2026 (Q1 FY26), -4% from a year earlier and -3% from the quarter before.
Was Haemonetics profitable in the first quarter fiscal 2026?
Operating profit was $53.9M (16.8% of revenue) and net earnings $34.0M.
Source: Haemonetics 10-Q on SEC EDGAR.